Twenty-three healthy volunteer subjects received a single dose of amphotericin B colloidal dispersion or placebo (4:2) in a double-blind, randomized, dose-escalating design. Doses ranged from 0.25 to 1.5 mg/kg of body weight. The medication was administered via intravenous infusion at a rate of 0.5 mg/kg/h. Plasma amphotericin B concentrations increased with increasing doses, resulting in a linear increase in the amphotericin B area under the curve. Concentrations in plasma decreased rapidly upon discontinuation of the infusion, indicating rapid tissue distribution. A log-linear biexponential elimination phase was observed. A three-compartment open model was used to describe the distribution and elimination of amphotericin B. The mean terminal elimination half-life ranged from 86 h at the 0.25-mg/kg dose level to 244 and 235 h at the 1.0-and 1.5-mg/kg dose levels, respectively. Mean total body clearance ranged from 219 to 284 ml/kg/h. The volume of distribution increased with dose, from 3.37 liter/kg at the 0.25-mg/kg dose to 7.92 liter/kg at the 1.5-mg/kg dose. At the lowest dose level, 0.25 mg/kg, the medication was generally well tolerated. Progressive increases in the dose led to increasing side effects. At the 1.5-mg/kg dose level, 50% of the patients on active medication experienced nausea, vomiting, and chills. Physical examinations, ophthalmologic examinations, and clinical laboratory parameters remained within normal limits compared with those obtained during prestudy examinations.
Amphotericin B has been used in the treatment of moderate to severe fungal infections for 30 years (14) . The medication continues to be widely used, despite the occurrence of dose-limiting toxicities, primarily renal tubular acidosis (14, 17) . In addition, approximately 20 to 50% of patients treated with amphotericin B develop acute reactions such as fever, chills, nausea, and vomiting (5, 14, 17) . The pharmacokinetics of amphotericin B are not well known. There have been several reports of studies on limited numbers of patients which have provided basic information on the disposition of the compound (3) (4) (5) 16) . Adult patients exhibit a large volume of distribution, 3 to 4 liters/kg, and a long terminal elimination-phase half-life, which ranges from 11 to 16 days (3, 5) . Studies in children demonstrate a higher clearance rate and shorter half-lives, although concentrations in plasma were measured for a limited time following treatment with amphotericin B (4, 16) .
Amphotericin B is available as a desoxycholate micellar solution (17) . A new formulation has been developed with the goal of increasing the tolerability of the drug. It consists of a cholesteryl sulfate complex of amphotericin B, the amphotericin B colloidal dispersion (ABCD; Liposome Technology, Inc.). ABCD is a stable complex of amphotericin B and cholesteryl sulfate in a 1:1 molar ratio. The lyophilized product is stable for 6 months at 50°C (10) . In vitro incubation studies with fresh human blood have shown that the drug-lipid complex does not result in hemolysis of erythrocytes and that binding to plasma lipoproteins is less than that observed with Fungizone (10) . Studies in animals have shown a significantly altered distribution of the com-* Corresponding author.
pound, particularly in the kidneys (10) . In these studies in animals, a reduction in the amount of drug taken up by renal tissue was associated with a reduction in the renal toxicity normally associated with amphotericin B treatment.
The purpose of this study was to assess the tolerance and pharmacokinetics of amphotericin B following a single intravenous infusion of ABCD administered to healthy volunteers.
MATERIALS AND METHODS
Twenty-three healthy male subjects (age range, 19 to 38 years; weight range, 63 to 95 kg) were enrolled in the study. Subjects were within 20% of ideal body weight on the basis of height and body frame (12) . Volunteers were accepted into the study on the basis of a prestudy medical history, physical examination, ophthalmologic examination, electrocardiogram, and laboratory tests of blood and urine. The study was approved by the Institutional Review Board of the University of Utah Medical Center. All subjects provided written informed consent.
Subjects were confined for the duration of the study. The study medication consisted of a 1-mg test dose followed (24 h later) by doses of 0.25, 0.5, 1.0, and 1.5 mg of ABCD or matching placebo (5% glucose with multivitamin) per kg of body weight. Dosing was performed in a double-blind fashion. Neither the subjects nor the clinical staff were able to break the study blind on the basis of the appearance of the dosing solutions. Subjects were randomly assigned to receive active drug or placebo (4:2) in each group at dose levels of 0.25, 0.5, 1.0, and 1.5 mg of ABCD per kg. ABCD was infused at a rate of 0.5 mg/kg/h, resulting in infusion times of 0.5, 1, 2, and 3 h for the 0.25-, 0.5-, 1-, and 1.5-mg/kg doses of ABCD, respectively. Vital signs, including blood pressure, pulse, and oral temperature, were measured periodically following each dose. Clinical laboratory tests and urine collections were performed prior to and following administration of each dose.
Blood samples were obtained prior to administration of the study dose; at the midpoint and end of the infusion; and at 15 and 30 min; 1, 2, 4, 7, 10, 24, and 48 h; and 7, 14, 21, and 28 days postinfusion. Samples were collected from the arm opposite the infusion site. Adverse experiences were recorded throughout the study. Subjects were discharged after collection of the blood sample at 48 h, with the remaining samples collected during outpatient visits.
Samples were stored at <-20'C until they were shipped to the analytical laboratory (Bio Research Laboratories, Ltd., Montreal, Quebec, Canada). Samples were analyzed for amphotericin B concentration by reversed-phase high-performance liquid chromatography on a Waters Micro-Bondapak column (0.39 by 30 cm; particle size, 10 ,um; Waters, Milford, Mass.) with a reversed-phase, slurry-packed Nucleosil C18 precolumn (Alltech Associates Inc., Deerfield, Ill.). The mobile phase was acetonitrile-water (40:60 [vol/vol]) containing 0.25 mM disodium EDTA at a flow rate of 1.0 ml/min. Amphotericin B was monitored at 328 nm by UV detection (Lambda Max model 481; Waters). Solid-phase extraction on disposable Bond Elut C18 extractions columns (Analytichem, Harbor City, Calif.) were used for initial sample cleanup. Calibration standards and quality control samples were created by spiking blank plasma with amphotericin B in dimethyl sulfoxide-methanol (1:1). The assay was linear over the range of 10 to 2,000 ng/ml. The sensitivity of the assay was defined at the lower limit of detection, i.e., 10 ng/ml. Recovery of amphotericin B from plasma averaged 80%. Interday precision expressed as a relative standard deviation of daily means was less than 10% at 30 ng/ml. Results of the assay were accepted if the within-run quality control samples were within 10% of the known concentration and results for duplicate assays of unknown samples did not deviate by more than 15%.
Subject demographics and incidence of adverse events were summarized by descriptive statistics. Vital signs measurements and laboratory values were analyzed by repeat measures analysis of variance (StatView 512+; Brainpower Inc., Calabasa, Calif.). A repeat measures three-way analysis of variance was performed for subjects, treatment groups (dose level), and days of measurement. The reported P values were corrected for multiple testing by the number of multiple replicate tests i.e., P value times n, analogous to the Bonferroni method (13) . Significance was set at P < 0.05.
Pharmacokinetic analyses included calculation of noncompartmental parameters and least-squares estimations for multiexponential parameters. Noncompartmental parameters were calculated as follows: Cmax = maximum measured concentration in plasma; AUC = area under the plasma concentration-time curve determined by the trapezoidal method (the terminal phase was calculated as Ct/klast; see below); Ct = last measured value of the concentration in plasma; klast = terminal first-order rate constant; TBC = total body clearance (CL) = dose/AUC; Varea = volume of distribution = CL/klast; Vss = volume of distribution at steady state = dose x (AUMC)/(AUC)2 -(T x dose)/(2 x AUC), where AUMC is the area under the first moment curve (plasma concentration x time versus time), and T is the time of infusion. AUC was corrected for residual drug present following the 1-mg test dose. When A three-term exponential model provided the best leastsquares fit for most subjects. Distribution and elimination rate constants for the three-compartment analysis are given in Table 2 . The coefficients of determination indicated that an adequate fit of the data was obtained for all subjects. In some subjects, insufficient data were available for the threecompartment model; therefore, a two-compartment model was used. Two subjects from the 1.5-mg/kg dosing group (subjects 19 and 21) exhibited a large decline in the concentration in plasma following the end of the infusion which led to large estimates for the distribution rate constant. These two estimates were not included in the mean data for this dosing group (Table 2 ). An example of the three-compartment fit of the individual concentration in plasma data is shown in Fig. 3 Table 3 . No clinically significant changes were noticed in the poststudy physical examinations, with the exception of ongoing phlebitis for subjects 19 and 24.
Vital signs were within normal limits for the majority of subjects. Statistically significant differences between subject groups were observed for diastolic blood pressure and oral temperature. Mean diastolic blood pressure was 62 mm Hg for subjects receiving 1.0 mg/kg versus the overall mean of 67 mm Hg (P = 0.008). Mean temperature reached a maximum value 2 h following the end of the infusion and was elevated for subjects in the 1.5-mg/kg dosing group, 37.8°C versus an overall mean of 37.0°C (P = 0.0016). Systolic blood pressure and heart rate were not statistically different (P = 0.0628 and P = 0.0832, respectively). Clinical laboratory parameters were assessed daily. There were no clinically significant changes in complete blood count, serum chemistry, or urinalysis during the study. All four dose levels were administered in the study without 
DISCUSSION
The disposition of amphotericin B following intravenous ABCD dosing was similar to those described for amphotericin B in previous reports (3) (4) (5) 16 ). Measurement of concentrations in plasma for 4 weeks following a single dose of ABCD represents a more complete assessment of amphotericin B pharmacokinetics than those provided in previous reports. The three-compartment model provided the best fit of the observed distribution and elimination phases of the compound. The initial distribution of amphotericin B occurred rapidly at all dose levels. Although few blood samples were collected during the distribution phase, most subjects exhibited a distribution-phase half-life of 2 to 5 min. An improved characterization of the distribution phase could be achieved by increasing the number of samples collected in the first few minutes following the end of the infusion. The poor fit of the three-term exponential function in subjects 19 and 21 was most likely due to this inadequate number of samples and the timing of the samples and does not indicate pharmacokinetic differences in these subjects. The biexponential elimination phase has been observed in previous studies of amphotericin B (3) (4) (5) 16) . Concentrations in plasma were measured for 12 and 18 days following the final dose of medication in two patients, as reported by Atkinson and Bennett (3) . The elimination-phase half-life of amphotericin B in these two patients was approximately 15 days (360 h). Both patients, however, exhibited renal insufficiency, with creatinine clearances of 28 and 37 mllmin. Two other studies reporting pharmacokinetic data for amphoter- icin B collected concentration-in-plasma data for approximately 24 h following a dose; these data provided limited information on the terminal elimination of the drug (4, 16) . A half-life of 11 days was reported by Chabot et al. (5) Amphotericin B is highly bound to the lipoproteins, erythrocytes, and cholesterol present in plasma and in tissues throughout the body (6, 7, 14) . The primary storage site appears to be the liver (6) . Liposomal forms of the drug are believed to be rapidly taken up by the reticuloendothelial system, thereby reducing binding to cholesterol and plasma membranes (17) . The cholesteryl sulfate complex should achieve a similar decrease in plasma membrane lipoprotein binding and lead to reduced associated toxicity, as has been observed in animal studies (10) .
The acute side effects seen after administration of ABCD were those typically seen with Fungizone (7) . No unique side effects were reported. The incidence of side effects increased with dose level. At the highest dose level, 1.5 mg/kg, two volunteers experienced nausea, vomiting, and chills. These acute side effects are commonly seen in premedicated patients treated with Fungizone at dose levels two to three times lower, 0.5 to 0.75 mg/kg (14, 17) . When a dose of 0.25 mg of Fungizone per kg was given to healthy volunteers, side effects similar to those reported at the 1.5-mg/kg ABCD level were reported (9) . In the 1.5-mg/kg ABCD dosing group, three subjects complained of pain at the site of infusion. This could be related to local irritation. Tachycardia and fever were present in two subjects in the 1.5-mg/kg dosing group.
Laboratory tests assessing renal and hepatic status were of particular interest. There were no clinically significant differences in blood urea nitrogen, creatinine, urine osmolality, or liver chemistry tests. Blood urea nitrogen and creatinine were measured approximately 4 h after administration of the dose of medication in an attempt to detect any transient effects. They were also measured daily during the study. The first voided urine sample obtained following administration of the dose of medication also showed no significant changes. No changes were observed in the poststudy physical and ophthalmologic examinations, with the exception of ongoing phlebitis for two of the volunteers, who reported pain at the infusion site. The phlebitis resolved slowly following completion of the study.
The pharmacokinetics of amphotericin B following infusions of ABCD do not differ significantly from those of Fungizone. The cholesteryl complex of amphotericin B may reduce renal tissue binding, which appears to lead to the renal tubular acidosis which develops with amphotericin B treatment. Future trials in patients with systemic fungal infections will determine the usefulness of this new formulation.
